Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hESC-derived RPE in retinitis pigmentosa (RPE65/LRAT/MerTK)
2024-513662-18-00Phase 2Authorised
- Sponsor
- Centre d'Etude des Cellules Souches
- Start
- Jun 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ISTEM-01 in retinitis pigmentosa (RP) (2 cohorts), sponsored by Centre d'Etude des Cellules Souches. Primary endpoint: Safety and tolerability. Planned start Jun 2024; status: authorised.
02
Drugs
ISTEM-01
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on 2024-513662-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513662-18-00.